RO7771950
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for RO7771950, covering 2026-04-09 to 2026-04-09. Get the full timeline:
Most recent: Clinical Trial Update: RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive [Phase 2, Phase 3]